BioSpace News Archive

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 3 clinical trial of OTIVIDEX in Ménière’s disease. A total of 149 patients have been enrolled in the trial, exceeding the target of 142 patients. Following randomization to treatment with a single intratympanic injection of OTIVIDEX or placebo, patients ar

- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today announced that an abstract detailing additional analyses of the data from its Phase 2a BALANC

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that a manuscript detailing the baseline characteristics from GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart F ailure), the Phase 3 event driven cardiovascular out

Micron Medical (“Micron” or “the Company”), a privately-held medical device company engaged in the development, manufacture and pre-commercialization of innovative wireless, minimally invasive, electroceutical solutions for urological conditions, today announced the appointment of Dr. Mark Landy as Chief Executive Officer, effective immediately. Dr. Landy, who is also joining the Company’s board of directors, has over 20 years of global leade

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to nine new employees.

Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, District of New Jersey, regarding Agreement of Settlement. UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY TRENT NICHOLS and SHARON NICHOLS, derivatively on behalf of COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC., Plaintiffs, vs. ELLI

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the availability of the first Food and Drug Administration (FDA)-approved generic versions of TRUVADA ®i and ATRIPLA ®i tablets. “As the global leader in producing and supplying generics, Teva is excited to launch these medications which further our commitment to deli

Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Hemodynamic Instability and Respiratory

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20 th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt Foehr, President and Chief Operation Officer Matt Korenberg, Chief Financial Officer

Case report demonstrated rapid resolution of hypoxemia and mobility and potential benefit of lenzilumab beyond the initial acute hyper-inflammatory window After 13 weeks of hospitalization, administration of lenzilumab resulted in rapid improvement in oxygenation and subsequent discharge BURLINGAME, Calif.--( BUSINESS WIRE )-- Humanigen, Inc. , (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused o